Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.

Authors

null

Melissa Lynne Johnson

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Melissa Lynne Johnson , Ross A. Soo , Yi-Long Wu , Navid Baktash , Daniela Maier , Sabina Eigenbrod-Giese , Tatsuya Yoshida

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT06151574

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS8654)

DOI

10.1200/JCO.2024.42.16_suppl.TPS8654

Abstract #

TPS8654

Poster Bd #

515a

Abstract Disclosures